Passive and active targeting strategies for the delivery of the camptothecin anticancer drug: a review
- PDF / 830,756 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 21 Downloads / 202 Views
REVIEW
Passive and active targeting strategies for the delivery of the camptothecin anticancer drug: a review Anindita Behera1 · Santwana Padhi2 Received: 8 May 2020 / Accepted: 1 June 2020 © Springer Nature Switzerland AG 2020
Abstract Cancer is the second highest cause of death globally, with about 70% of deaths occurring in low- or middle-income countries, thus calling for efficient cures. Nanotechnology research has evidenced numerous therapeutic innovations that target the tumor tissues either passively or actively. Camptothecin is a potent anticancer drug which has shown appreciable antitumor activity against a broad spectrum of cancers such as breast, ovarian, colon, lung and stomach. Nonetheless, applications of camptothecin are limited by water insolubility, rapid conversion of its bioactive lactone form to inactive carboxylate under physiological conditions, drug resistance and off-target side effects. Here, we review the delivery of camptothecin by active and passive targeting for anticancer activity. We discuss the mechanism of action and the novel targeted drug delivery platforms that have been explored for the delivery of camptothecin for the treatment of solid tumors. Keywords Camptothecin · Nanotherapeutics · Topoisomerase I · Enhanced permeability and retention · Passive targeting · Active targeting · Solid tumor · Nanomaterial Abbreviations ERP Enhanced permeation and retention effect Topo-I Deoxyribonucleic acid topoisomerase I SUMO Small ubiquitin-like modifier TCR Transcription coupled repair TDP 1 Tyrosyl-deoxyribonucleic acid phosphodiesterase BALB/c Bagg albino Β-GP Glycerol-2-phosphate RIF-l Radiation-induced fibrosarcoma-1 HeLa Human cervical cell line VEGF Vascular endothelial growth factor MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide SMNs Small molecular nanodrugs LHRH Luteinizing hormone-releasing hormone BH3 BCL-2 homology 3 FR Folate receptor PFC Perfluorocarbon * Anindita Behera [email protected] 1
School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar, Odisha, India
KIIT Technology Business Incubator, KIIT Deemed to be University, Bhubaneswar, Odisha, India
2
ADV Acoustic droplet vaporization US Ultrasound MSNs Mesoporous silica nanoparticles CdS Cadmium sulfide HCN Herceptin-functionalized camptothecin nanoparticle HER2 Human epidermal growth factor receptor 2 PDSG Poly[2-(pyridin-2-yldisulfanyl)]-graftpoly(ethylene glycol)
Introduction Cancer is known to be a highly complex disease caused by defect or instability of the genes causing alteration in cellular pathology such as abnormal growth and replication of the cells due to genetic mutation, chromosome translocation, gene malfunction and disabled apoptosis (Mansoori et al. 2007). It is a major public health problem worldwide being the leading cause of death in developed countries and second leading cause of death in developing countries. An estimated 12.66 million people were diagnosed with cancer across the world in 2008, and 7.
Data Loading...
